M. Suárez

Her-2/neu Expression in Prostate Cancer

J. Lloreta, M. Salido, J. Carles, 2004, Clinical Cancer Research.

Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

J. Carles, J. Albanell, I. Tusquets, 2006 .

Intratumoral heterogeneity of HER2/neu and topoisomerase IIalpha in breast cancer: a case with clonal monosomy 17.

S. Serrano, F. Solé, M. Salido, 2004, Cancer genetics and cytogenetics.

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

S. Serrano, F. Solé, M. Salido, 2005, Breast Cancer Research.

Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.

E. Campo, S. Serrano, J. Albanell, 2006, Endocrine-related cancer.

Characterization of HER1 (c-erbB1) Status in Locally Advanced Breast Cancer Using Fluorescence in situ Hybridization and Immunohistochemistry

S. Serrano, F. Solé, M. Salido, 2005, Tumor Biology.

Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

E. Campo, S. Serrano, J. Albanell, 2006 .

Activation of nuclear factor- j B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

E. Campo, S. Serrano, J. Albanell, 2006 .

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

J. Carles, E. Gallardo, J. Gayo, 2010, International Journal of Radiation Oncology, Biology, Physics.

Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.

J. Carles, J. Albanell, I. Tusquets, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.